BSBruno Moreira Soares

Bruno Moreira Soares

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bruno Moreira Soares has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    EFEITOS DA ADMINISTRAÇÃO SUBCRÔNICA DE Baccharis dracunculifolia (BR 10 2012 020540-8 A2) EM MODELO ANIMAL DE DIABETES TIPO I

    by Nilane Françoise Patel, Bruno Moreira Soares, Daniele Fernanda Renzi, Andressa Razera Pezoti, Jéssica Wouk, Carlos Ricardo Maneck Malfatti, Luiz Augusto Silva, Vanusa Karini Savighago Savighago, Felipe Nathanael Coelho Vaz

    O Diabetes mellitus (DM) destaca-se como um problema de saúde pública mundial. Diante disso, várias espécies de plantas vêm sendo utilizadas para tratar e/ou combater os sintomas do DM. O objetivo deste estudo foi avaliar os efeitos da ingestão subcrônica do extrato de Baccharis dracunculifolia, em modelo animal de DM. Foram utilizados 56 ratos machos da linhagem Wistar, tratados por 28 dias. O modelo de DM tipo I foi induzido pela administração de 60 mg/kg de estreptozotocina. O grupo CB demonstrou 14,8% (p<0.05) menor consumo de ração que o grupo DB200. Quanto à ingestão hídrica, o grupo CDT teve maior ingesta (44,1%; p<0.05) com relação aos grupos tratados. Na glicemia capilar em jejum e pós-prandial, os grupos tratados apresentaram redução de 54,3% a 63,4% ao jejum e 37,9% a 45% no pós-prandial. Conclui-se que o extrato metanólico de B. dracunculifolia reduziu os níveis glicêmicos em ratos diabéticos tipo I.

  • Open Access

    HPV positive, wild type TP53, and p16 overexpression correlate with the absence of residual tumors after chemoradiotherapy in anal squamous cell carcinoma

    by Paulo C. Soares, Eliana S. Abdelhay, Luiz Claudio S. Thuler, Bruno Moreira Soares, Samia Demachki, Gessica Valéria Rocha Ferro, Paulo P. Assumpção, Leticia Martins Lamarão, Luis Felipe Ribeiro Pinto, Rommel Mario Rodríguez Burbano

    Anal residual tumors are consensually identified within six months of chemoradiotherapy and represent a persistent lesion that may have prognostic value for overall survival. The aim of this study was to evaluate the association of HPV and HIV status, p16 expression level and TP53 mutations with the absence of residual tumors (local response) in Squamous Cell Carcinoma (SCC) of the anal canal after chemoradiotherapy. We performed a study on 78 patients with SCC of the anal canal who submitted to chemoradiotherapy and were followed for a six-month period to identify the absence or presence of residual tumors. HPV DNA was identified by polymerase chain reaction and direct sequencing, HIV RNA was detected by TaqMan amplification, p16 expression was detected by western blotting, and the mutational analysis of TP53 was performed by direct sequencing; additionally, samples carrying mutations underwent fluorescent in sit hybridization. The evaluation of the tumor response to treatment was conducted six months after the conclusion of chemoradiotherapy. The following classifications were used to evaluate the outcomes: a) no response (presence of residual tumor) and b) complete response (absence of residual tumor). The significant variables associated with the absence of residual tumors were HPV positive, p16 overexpressed, wild-type TP53, female gender, and stages I and II. Only the presence of HPV was independently correlated with the clinical response; this variable increased the chances of a response within six months by 31-fold. The presence of HPV in tumor cells was correlated with the absence of a residual tumor. This correlation is valuable and can direct future therapeutic approaches in the anal canal.